Related Experiment Video
Updated: May 16, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Is it time to revisit standard post-remission therapy?
1Harvard Medical School, Boston, MA, USA. rstone@partners.org
Best Practice & Research. Clinical Haematology
|December 4, 2012
Summary
Improving post-remission therapy for acute myeloid leukemia (AML) involves risk-adapted strategies and considering genetic data. Future treatments may include new agents or maintenance therapy for older patients.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Post-remission therapy is crucial for acute myeloid leukemia (AML) patients.
- Current strategies aim to optimize outcomes after initial treatment.
Purpose of the Study:
- To review and discuss strategies for enhancing post-remission therapy in AML.
- To highlight the role of risk stratification and emerging therapeutic options.
Main Methods:
- Review of current risk-adapted treatment protocols for younger AML adults.
- Discussion of genetic factors and minimal residual disease (MRD) in treatment selection.
- Exploration of potential future therapies for older AML patients.
Main Results:
- Risk-adapted strategies, including allogeneic stem cell transplantation and high-dose ara-C, are employed for younger AML patients.
- Cytogenetic and genetic data, along with MRD levels, can inform therapeutic choices.
- Novel agents and maintenance therapies, such as DNA methyltransferase inhibitors, are being investigated for older AML patients.
Conclusions:
- Personalized, risk-adapted approaches are key to improving AML post-remission outcomes.
- Integrating genetic information and MRD monitoring enhances treatment selection.
- Innovative therapeutic strategies are needed to address the challenges in treating older AML patients.
